(Q41251653)

28 September 2017

1 reference

title

Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production (English)

1 reference

28 September 2017

1 reference

Zuckerman JN

1

1 reference

28 September 2017

1 December 1996

1 reference

Journal of Medical Virology

28 September 2017

1 reference

28 September 2017

50

1 reference

28 September 2017

4

1 reference

28 September 2017

283-288

1 reference

Antibody response to pre-S2 and hepatitis B virus induced liver damage

28 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B Vaccine in Health Care Personnel: Safety, lmmunogenicity, and Indicators of Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B vaccine: immunogenicity and follow-up including two year booster doses in high-risk health care personnel in a London teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B vaccine: responder status and timing of additional booster doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B vaccination: protection for how long and against what?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

The immune response to hepatitis B vaccine in humans: inheritance patterns in families

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Is nonresponsiveness to hepatitis B vaccine due to latent hepatitis B virus infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Immune response to hepatitis B virus proteins: relevance of the murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Immunization against hepatitis B--what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Genetic prediction of nonresponse to hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Immunologic Prevention of Human Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B vaccination: how long does protection last?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Immune response to hepatitis B revaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

HLA linked immune response to S and pre-S2 gene products in hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B vaccination follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Use of immunomodulators (thymopentine) in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Acquired forms of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Persistence of anti-HBs among health care personnel immunized with hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

Hepatitis B vaccine boosting: the debate continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199612%2950%3A4%3C283%3A%3AAID-JMV1%3E3.0.CO%3B2-4

10.1002/(SICI)1096-9071(199612)50:4<283::AID-JMV1>3.0.CO;2-4

21 January 2018

Identifiers

DOI

1 reference

28 September 2017

1 reference

PubMed ID

8950683